Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational Study, in Patients With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) According to ASAS Criteria, naïve to Conventional (cDMARDs), Targeted (tsDMARDs) and Biological DMARDs (bDMARDs) - SIRENA Study (Spondyloarthritis Italian Registry: Evidence From a National Pathway)

NCT03131661 is registered in ClinicalTrials.gov with Janssen-Cilag S.p.A. as lead sponsor.

NCT NCT03131661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03131661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational Study, in Patients With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) According to ASAS Criteria, naïve to Conventional (cDMARDs), Targeted (tsDMARDs) and Biological DMARDs (bDMARDs) - SIRENA Study (Spondyloarthritis Italian Registry: Evidence From a National Pathway)
Lead sponsor
Janssen-Cilag S.p.A.
Phase
Observational
Overall status
Completed
Start date
June 9, 2017
Completion date
July 28, 2021
Enrollment
351 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

spondyloarthritis, axial and peripheral